Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PROTAG-8

Financiado

Cerrado

Protein degraders for targeting galectin-8

In the PROTAG-8 project, we aim to target galectin-8 by protein degradation using proteolysis targeting chimeras or shortly, PROTACs. Galectin-8 is a galactoside-binding lectin that exists as a soluble intracellular and extracellu... ver más

31/08/2026

Presupuesto desconocido

Líder del proyecto

UNIVERZA V LJUBLJANI No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-01

HORIZON-WIDERA-2022-TALENTS-04-01: Fostering balanced brain circulatio... Expected Outcome:This action will build on the MSCA Postdoctoral Fellowships 2022 action (HORIZON-MS...

I+D

Cerrada

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 23 meses Fecha Inicio: 2024-09-01
Fecha Fin: 2026-08-31

Líder del proyecto

UNIVERZA V LJUBLJANI No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In the PROTAG-8 project, we aim to target galectin-8 by protein degradation using proteolysis targeting chimeras or shortly, PROTACs. Galectin-8 is a galactoside-binding lectin that exists as a soluble intracellular and extracellular receptor, with an extensive exchange between the membrane-bound and cytosolic forms. Its inhibitors are potential new anticancer drugs, but the affinity of classical galectin-8 inhibitors is in the low micromolar range, hardly sufficient for their use as drug molecules. The overarching aim of PROTAG-8 is to explore whether the PROTAC method can be implemented for galectin-8 and to answer the question of whether PROTACs offer advantages over classical selective galectin-8 ligands. Since PROTACs need only bind their targets with high selectivity and with an affinity high enough to stabilize the ternary complex between the protein of interest and the E3 ligase, the affinity in the micromolar range could be sufficient for their activity, unlike conventional ligands. The current state-of-the-art in the development of PROTACs focuses only on intracellular proteins, but galectin-8 exists as both an intracellular and extracellular protein. Based on this fact, we want to find out whether such a receptor, which occurs both in the cytosol and in the extracellular matrix, can be effectively targeted with PROTACS and its activity modulated. This scientific question will be tackled by a highly-qualified PhD Nives Hribernik with international experience in glycochemistry, medicinal chemistry and chemical biology, and is expected to be an excellent springboard to her independent scientific career. The project proposal includes renowned principal investigators from two academic institutions: Prof. Dr. Marko Anderluh from the University of Ljubljana (Slovenia), and Prof. Dr. Ulf Nilsson and Prof. Derek Logan from Lund University (Sweden), giving the PROTAG-8 international and interdisciplinary background.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores